First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million
None of the observations are related to data integrity and management believes that they are addressable
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
The designation recognizes Seeq's expertise in enabling faster insights and better business outcomes for life sciences customers, including Bristol Myers Squibb, with advanced analytics innovations.
The current ruling will assure the safety of the use of Ranitidine for Indian patients
Subscribe To Our Newsletter & Stay Updated
